

George Nesr

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1027955/publications.pdf>

Version: 2024-02-01

12
papers

66
citations

1684188

5
h-index

1588992

8
g-index

13
all docs

13
docs citations

13
times ranked

103
citing authors

#	ARTICLE	IF	CITATIONS
1	TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2021, 193, 346-355.	2.5	18
2	Immune thrombocytopenia flare with mild COVID-19 infection in pregnancy: A case report. <i>British Journal of Haematology</i> , 2020, 190, e146-e148.	2.5	12
3	MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia. <i>Haematologica</i> , 2019, 104, 2206-2214.	3.5	10
4	Outcome of hospitalized patients with hematological malignancies and COVID-19 infection in a large urban healthcare trust in the United Kingdom. <i>Leukemia and Lymphoma</i> , 2021, 62, 469-472.	1.3	7
5	Autoimmune haemolytic anaemia and a marked rise in the lymphocyte count associated with COVID-19 in a patient with treatment-naïve chronic lymphocytic leukaemia: a case report. <i>British Journal of Haematology</i> , 2020, 190, e326-e328.	2.5	6
6	Dose Reduction of First and Second Generation TKIs Is Effective in the Maintenance of Major Molecular Response and May Predict Successful Tfr in CML Patients. <i>Blood</i> , 2018, 132, 3007-3007.	1.4	4
7	The influence of salivary amylase on total amylase elevation in CML patients treated with TKI therapy: a case series of 3 patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 3333-3334.	1.3	2
8	Plasma cell leukaemia with "lymphoid-like morphology" in peripheral blood. <i>International Journal of Laboratory Hematology</i> , 2022, 44, 10-12.	1.3	2
9	Outcome of COVID-19 in patients with chronic myeloid leukemia: A single centre UK experience. <i>Journal of Medical Virology</i> , 2022, 94, 1274-1276.	5.0	2
10	T-cell prolymphocytic leukaemia in a patient with chronic myeloid leukaemia receiving nilotinib: first documented report. <i>Journal of Clinical Pathology</i> , 2019, 72, 511-512.	2.0	1
11	Platelet function in patients with chronic myeloid leukemia treated with asciminib. <i>Leukemia and Lymphoma</i> , 2020, 61, 3021-3023.	1.3	1
12	Improvement in mortality of hospitalized patients with hematological malignancies in the 2nd wave of COVID-19 in the UK: experience of a large London NHS trust. <i>Leukemia and Lymphoma</i> , 2021, , 1-4.	1.3	1